|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 25 MASSACHUSETTS AVENUE, NW |
Address2 | SUITE 600 |
City | WASHINGTON |
State | DC |
Zip Code | 20001-7400 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Chicago |
State | IL |
Zip Code | 60611-5885 |
Country | USA |
|
5. Senate ID# 2877-12
|
||||||||
|
6. House ID# 304640000
|
TYPE OF REPORT | 8. Year | 2018 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: George E. Cox III, JD |
Date | 10/19/2018 1:58:10 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 6147, Interior, Environment, Financial Services, and General Government Appropriations Act, 2019, provisions related to DTC advertising
H.R. 6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019, provisions related to DTC advertising/Durbin-Grassley amendment, funding for NIH, National Diabetes Prevention Program, community health centers, National Health Service Corps, and Teaching Health Center Graduate Medical Education programs
H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to telehealth
Consolidated Appropriations Act (P.L. 115-141), provisions relating to Conrad 30 reauthorization
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Richard |
Deem |
|
|
|
Cynthia |
Brown |
|
|
|
Todd |
Askew |
|
|
|
Jason |
Marino |
|
|
|
Thomas |
Roberge |
|
|
|
George |
Cox |
III |
|
|
Sylvia |
Trujillo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 1267, Personal Health Investment Today (PHIT) Act, all provisions
H.R. 4240, Public Safety and Second Amendment Rights Protection Act of 2017, all provisions
H.R. 6142, Reducing Drug Waste Act of 2018, all provisions
H.R. 6301, Promoting High-Value Health Care Through Flexibility for High Deductible Health Plans Act of 2018, all provisions
H.R. 6199, Restoring Access to Medication and Modernizing Health Savings Accounts Act of 2018, all provisions
H.R. 6305, Bipartisan HSA Improvement Act of 2018, all provisions
H.R. 6306, Health Care Security Act of 2018, all provisions
H.R. 6313, Responsible Additions and Increases to Sustain Employee Health Benefits Act of 2018, all provisions
H.R. 6314, Health Savings Act of 2018, all provisions
H.R. 6317, Primary Care Enhancement Act of 2018, all provisions
H.R. 6082, Overdose Prevention and Patient Safety Act, all provisions
H.R. 6, Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, all provisions
S. 2680, Opioid Crisis Response Act of 2018, all provisions
S. 3120, Helping to End Addiction and Lessen (HEAL) Substance Use Disorders Act of 2018, provisions relating to human services
H.R. 6733, Know the Cost Act of 2018, all provisions
S. 2554, Patient Right to Know Drug Prices Act, all provisions
S. 2020, Cyber Shield Act of 2017, all provisions
H.R. 394, Restoring Access to Medication Act of 2017, all provisions
S. 85, Restoring Access to Medication Act of 2017, all provisions
H.R. 1375, Prescriber Support Act of 2017, all provisions
S. 1016, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2017, provisions relating to telehealth
S. 2456, CARA 2.0 Act of 2018, all provisions
H.R. 4825, Marijuana Effective Drug Studies (MEDS) Act of 2018, all provisions
S. 1112, Maternal Health Accountability Act of 2017, all provisions
Diagnostic Accuracy and Innovation
Prescription Drug Pricing
Affordable Care Act (ACA) risk-adjustment program
42 CFR Part 2/Substance abuse confidentiality regulations
Software as a Medical Device (SaMD)
SaMD Transparency
Certificate-of-Need Reform
Physician-Owned Hospitals
Augmented Intelligence (AI)
Cybersecurity
ACA Navigator program funding cuts
Electronic Health Records (EHR)
EHR Vendor Reporting Program
EHR Interoperability
In-Office Compounding
Opioids
Consent2Share demonstration
Prescription drug costs and pricing
Substance use disorder
Medical price transparency
Administrative burdens and simplification
Telehealth
Laboratory developed tests (LDTs)
Health Savings Accounts - Prescription requirement for over-the-counter medications
Electronic prescribing of controlled substances
Prescription Drug Monitoring Program (PDMP)
Federal prescription limits
Sunshine Act Regulation - Journal reprints and textbooks
Direct-to-consumer (DTC) advertising - prescription drug price disclosure
Biosimilar Regulations
Generic Drug Regulations
Pharmacy Benefit Managers (PBMs)
Surprise billing
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Richard |
Deem |
|
|
|
Cynthia |
Brown |
|
|
|
Todd |
Askew |
|
|
|
Lindsey |
Brill |
|
|
|
Jason |
Marino |
|
|
|
Thomas |
Roberge |
|
|
|
Andrew |
Wankum |
|
|
|
Margaret |
Garikes |
|
|
|
Shannon |
Curtis |
|
|
|
Laura |
Hoffman |
|
|
|
Sandy |
Marks |
|
|
|
Matthew |
Reid |
|
|
|
Koryn |
Rubin |
|
|
|
George |
Cox |
III |
|
|
Debra |
Cohn |
|
|
|
Sylvia |
Trujillo |
|
|
|
Paul |
Westfall |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
S. 898, Conrad State 30 and Physician Access Reauthorization Act, all provisions
H-1B visa backlog
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Citizenship & Immigration Services (USCIS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Richard |
Deem |
|
|
|
Cynthia |
Brown |
|
|
|
Todd |
Askew |
|
|
|
Jason |
Marino |
|
|
|
George |
Cox |
III |
|
|
Jennifer |
Brown |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
CVS-Aetna Merger
17. House(s) of Congress and Federal agencies Check if None
Justice - Dept of (DOJ)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Richard |
Deem |
|
|
|
Cynthia |
Brown |
|
|
|
George |
Cox |
III |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 6, Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, all provisions
H.R. 4143, Dialysis Patient Access To Integrated-care, Empowerment, Nephrologists, Treatment, and Services (PATIENTS) Demonstration Act of 2017, all provisions
S. 2065, Dialysis Patient Access To Integrated-care, Empowerment, Nephrologists, Treatment, and Services (PATIENTS) Demonstration Act of 2017, all provisions
H.R. 4554, Medicare Common Access Card Act of 2017, all provisions
H.R. 6309, Allowing Working Seniors to Keep Their Health Savings Accounts Act of 2018, all provisions
H.R. 6733, Know the Cost Act of 2018, all provisions
S. 2553, Know the Lowest Price Act of 2018, all provisions
S. 3120, Helping to End Addiction and Lessen (HEAL) Substance Use Disorders Act of 2018, provisions relating to Medicare and Medicaid
S. 2904, Medicaid Substance Use Disorder Treatment via Telehealth Act, provision relating to telehealth definition
S. 2910, Telehealth for Children's Access to Services and Treatment (TeleCAST) Act, provision relating to telehealth definition
H.R. 3528, Every Prescription Conveyed Securely Act, all provisions
S. 2460, Every Prescription Conveyed Securely Act, all provisions
H.R. 2687, Medicaid Coverage for Addiction Recovery Expansion Act, all provisions
S. 1169, Medicaid Coverage for Addiction Recovery Expansion Act, all provisions
S. 1291, Advancing Medical Resident Training in Community Hospitals Act of 2017, all provisions
S. 1016, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2017, provisions relating to telehealth
Medicare program: Medicare Access and Chip Reauthorization (MACRA) implementation
Medicare program: Merit-based Incentive Payment System (MIPS)
Medicare program: Regulatory Relief
Medicare program: Quality Payment Program (QPP)/Interoperability
Medicare program: QPP cost measures
Medicare program: Protecting Access to Medicare Act (PAMA) clinical lab issues/physician office labs
Medicare program: Part B drug reimbursement
Medicare program: Outpatient Prospective Payment System (OPPS)/Ambulatory Surgical Center (ASC) Payment System
Medicare program: Appropriate Use Criteria
Medicare program: Health IT
Medicare program: Office visit codes
Medicare program: Alternative Payment Models (APMs)
Medicare program: Accountable Care Organization (ACO)/Medicare Shared Savings Program (MSSP)
Medicare program: Graduate Medical Education (GME)
Medicare program: 2019 Medicare Physician Fee Schedule
Medicare program: Drug pricing/Competitive Acquisition Program, Part B to Part D, Medicare Advantage Step Therapy
Medicare program: Open Payments
Medicare program: Clinical laboratory fee schedule cuts
Medicare program: Evaluation & Management Codes
Medicare program: Misvalued codes
Medicare program: Outpatient Prospective Payment System (OPPS)/Ambulatory Surgical Centers (ASC) Payment System
Medicare program: Prior Authorization
Medicare program: Electronic Health Records (EHR)
Medicare program: Inpatient Prospective Payment System
Medicare program: Diabetes/payment
Medicare program: Diabetes Prevention Program
Medicare program: Opioids
Medicare program: Smart Cards
Medicare program: Value-based arrangements
Medicare program: Evaluation and Management proposals
Medicare program: Payment Model Technical Advisory Committee (PTAC)/model approval process
Medicare program: Medicare Advantage Qualifying Payment Arrangement Incentive (MAQI) demonstration
Medicare program: Pharmacy Benefit Managers (PBMs)
Medicare and Medicaid programs: Appropriate Use Criteria
Medicare and Medicaid programs: Cybersecurity
Medicare and Medicaid programs: Stark/Anti-Kickback/Value-based arrangements
Medicare and Medicaid programs: Electronic Health Records/certification
Medicare and Medicaid programs: Provider Enrollment, Chain and Ownership System (PECOS)/Medicare Enrollment/Revocations/Revalidations
Medicaid program: Marylands Medicaid Demonstration Waiver Amendment
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Richard |
Deem |
|
|
|
Cynthia |
Brown |
|
|
|
Todd |
Askew |
|
|
|
Lindsey |
Brill |
|
|
|
Dana |
Lichtenberg |
|
|
|
Jason |
Marino |
|
|
|
Thomas |
Roberge |
|
|
|
Andrew |
Wankum |
|
|
|
Margaret |
Garikes |
|
|
|
Shannon |
Curtis |
|
|
|
Laura |
Hoffman |
|
|
|
Sandy |
Marks |
|
|
|
Sharon |
McIlrath |
|
|
|
Matthew |
Reid |
|
|
|
Koryn |
Rubin |
|
|
|
Jason |
Scull |
|
|
|
George |
Cox |
III |
|
|
Jennifer |
Brown |
|
|
|
Debra |
Cohn |
|
|
|
Ashley |
McGlone |
|
|
|
Sylvia |
Trujillo |
|
|
|
Paul |
Westfall |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
Nicotine levels in tobacco products
Premium cigars - FDA regulation exemption
17. House(s) of Congress and Federal agencies Check if None
Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Richard |
Deem |
|
|
|
Cynthia |
Brown |
|
|
|
George |
Cox |
III |
|
|
Debra |
Cohn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOR
16. Specific lobbying issues
S. 808, Sports Medicine Licensure Clarity Act of 2017, all provisions
H.R. 1876, Good Samaritan Health Professionals Act of 2017, all provisions
H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018, all provisions
H.R. 302, FAA Reauthorization Act of 2018, all provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Richard |
Deem |
|
|
|
Cynthia |
Brown |
|
|
|
Todd |
Askew |
|
|
|
Dana |
Lichtenberg |
|
|
|
Thomas |
Roberge |
|
|
|
Andrew |
Wankum |
|
|
|
George |
Cox |
III |
|
|
Debra |
Cohn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Scope of Practice
Veterans Choice Program/Community Care Program transition
Tricare
Anywhere to Anywhere Initiative (Telehealth)
17. House(s) of Congress and Federal agencies Check if None
Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Richard |
Deem |
|
|
|
Cynthia |
Brown |
|
|
|
Margaret |
Garikes |
|
|
|
Jason |
Scull |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
EDU |
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |